Rx · Prescription onlyInjected under the skin
Pentadeca-Arginate
PDA
Tissue repair, stable form.
Your plan
$209/mo, $1,254 billed once for 6 months/mo
$1,254 billed once for 6 months · unused months refunded on a medical stop
No membership fee · this is the full price · free shipping · avg 4-week supply
- Medication, clinician care and dose adjustments, all in one price.
- ~28-day supply. Your clinician sets your exact dose, so yours may vary; your refill arrives as you finish the last one.
A licensed clinician on our care team reviews every request and prescribes only when it's clinically appropriate.
FDA status: Compounded medication, not FDA-approved.
What it's for
Who it's for
People interested in BPC-157 who want its newer relative.
How it's different
The same 15-amino-acid chain as BPC-157 with arginine in place of the acetate salt. It has less research behind it, not more.
How it works
Pentadeca-Arginate is a synthetic peptide designed as a stable analog of BPC-157. Like BPC-157, it is studied for accelerating tissue repair through blood-vessel growth and cell signaling. It is prescribed off-label based on preclinical research and clinical experience.
How to use it and what arrives
1 vial · lasts 4 weeks
3 mg/mL · 5 mL vial
- How
- Injected under the skin
- Where
- near the injury site
- How often
- 5 days a week
Good to know
Choose one or the other. Taking it together with BPC-157 has no logic.
What the research shows
Sold as a stabilised salt form of a BPC-157 sequence. We found no published human data on pentadeca arginate itself, and I say so plainly.
Human data
none published
We found no published human trial of pentadeca arginate and no peer-reviewed study of it as a separate molecule. Its name and sales claims are borrowed from BPC-157.
Narrative review of BPC-157 for musculoskeletal healing, PMC12446177BPC-157 base
three pilot studies
The BPC-157 sequence it is based on has been studied in only three small human pilot studies (knee pain, interstitial cystitis, and intravenous safety). Most of the evidence is animal work, and those findings do not transfer automatically to a different salt.
Narrative review of BPC-157 for musculoskeletal healing, PMC12446177Regulatory status
not approved
We found no FDA approval for pentadeca arginate. BPC-157 was nominated for FDA's compounding bulks lists and then appeared among withdrawn nominations; the FDA page, current as of April 22, 2026, still notes possible immunogenicity risks.
FDA, bulk drug substances nominated for compounding
Community timelines for this peptide are not measured outcomes; they are borrowed from BPC-157 practice. Product identity and purity for this salt are not established in public sources.
What this does not say
- We found no human outcome data for pentadeca arginate.
- A different salt can change stability and absorption; the BPC-157 data do not settle it.
- Injection-site reactions and other adverse events are not characterised for this product.
Sources
- Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy. Cells, 2020
- Unique features of human cathelicidin LL-37. Biofactors, 2015
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med, 2025
- Metabolic effects of a growth hormone-releasing factor (tesamorelin) in patients with HIV. N Engl J Med, 2007
- Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol, 1998
- Thymosin alpha 1: A comprehensive review of the literature. World J Virol, 2020
Safety
FDA status: Compounded medication, not FDA-approved.
Side effects and precautions
- Research peptides are prescribed off-label and carry more uncertainty than established therapies.
- Common, mild effects include redness, itching or a bump at the injection site, headache, or flushing in the first days.
- Some (IGF-1) require careful glucose monitoring.
Get care right away
- Stop and seek care for hives, swelling of the face or lips, or trouble breathing.
When it isn't prescribed
- Because these peptides support cell growth or immune signaling, they are not prescribed with an active cancer, a cancer under evaluation, or during pregnancy or breastfeeding.
Tell your clinician about every medication you take, every supplement, and your complete health history, including any autoimmune conditions.
Questions
How is PDA different from BPC-157?
It is chemically designed to be a more stable version of BPC-157. Preclinically they show similar effects; human evidence for both is early. Your clinician decides whether BPC-157 or PDA fits your situation better.
Why are these off-label?
Off-label means not FDA-approved for these specific uses, but prescribed by clinicians based on preclinical evidence and clinical experience. It is common in medical practice; your clinician explains the evidence and the gaps.
How often do I take it?
Usually a small subcutaneous injection once daily or a few times a week, depending on the peptide. Your clinician sets the schedule and adjusts it as needed. The kit includes everything.
What is the evidence really like?
Honest answer: early. Preclinical and animal data are promising; human data are limited or absent. Your clinician explains this plainly and monitors you closely. If you prefer established therapies, tell them.
Ready to start with Pentadeca-Arginate?
$209/mo · $1,254 billed once for 6 months
- Free shipping on every order
- No membership fee
- Same price at every dose
- HSA and FSA accepted
